XORTX Therapeutics Inc.: Form 20-F for the period ended Dec 31, 2021
Filed with the SEC on May 3, 2022 and accepted by EDGAR at May 3, 2022, 21:29 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Net income | 12 months2021-01-01 to 2021-12-31 | −CAD 1.7m | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −CAD 6.1m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | At period end2021-12-31 | CAD 18.9m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2021-12-31 | CAD 20.2m | ifrs-full:CurrentAssets |
| Total assets | At period end2021-12-31 | CAD 22.0m | ifrs-full:Assets |
| Current liabilities | At period end2021-12-31 | CAD 701.0k | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2021-12-31 | CAD 5.3m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2021-12-31 | CAD 16.7m | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2021-12-31 | 12,989,678 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001753926-22-000646. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.